title: Assessment of patient acceptability of medical treatment in case of non-viable first trimester pregnancy.
abstract: OBJECTIVE
  The aim of the present study was to assess patient acceptability and satisfaction with medical treatment (vaginal misoprostol) of non-viable first trimester pregnancy.
  
  
  METHODS
  A total of 64 women, treated with vaginal misoprostol for non-viable first trimester pregnancy between October 2012 and December 2012 at the First Department of Obstetrics and Gynecology Medical University of Warsaw, were included in this questionnaire-based study. Questions pertaining to advantages and disadvantages of misoprostol treatment as compared to potential surgical intervention were used. The respondents also determined whether they would choose medical treatment if they were to decide again. The Visual Analogue Scale (VAS) was used to assess pain and bleeding intensity.
  
  
  RESULTS
  Medical treatment was successful in 57 and surgical treatment was needed in 7 women. Average pain and bleeding intensity were 5.8 and 5.3, respectively. The most common side effects included diarrhea (27%), dizziness (22.2%), nausea (15.9%), and chills (15.6%). The most important advantages of misoprostol therapy were avoidance of the risk of uterine perforation (96.4%) and formation of intrauterine adhesions (74.6%), whereas the most significant disadvantages were prolonged bleeding (21.4%), pain (21.4%), and longer treatment duration (42.9%). Overall, 95.6% of the patients with successful treatment outcome declared they would choose this procedure if they were to decide again, as compared to 85.6% of women with treatment failure (p > 0.05).
  
  
  CONCLUSIONS
  Medical treatment with vaginal misoprostol is acceptable and well-tolerated by the vast majority of women with non-viable first trimester pregnancy. Satisfaction is expressed by both, respondents with successful as well as unsuccessful treatment outcome.
authors.forename: Paweł
authors.initials: P
authors.lastname: Tomasik
authors.forename: Aneta
authors.initials: A
authors.lastname: Zwierzchowska
authors.forename: Ewa
authors.initials: E
authors.lastname: Barcz
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods* / Q000706:statistics & numerical data; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data*; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D011044:Poland / Q000453:epidemiology; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D014592:Uterine Hemorrhage / Q000139:chemically induced; D016387:Women's Health
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol